UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 248

Sortiert nach

An appropriate choice for immunotherapy in malignant pleural mesothelioma

EBioMedicine, 2020-12, Vol.62, p.103057-103057, Article 103057

Fujimoto, Nobukazu

2020

Volltextzugriff (PDF)

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)

Clinical cancer research, 2019-09, Vol.25 (18), p.5485-5492

2019

Volltextzugriff (PDF)

Significance of secretory leukocyte peptidase inhibitor in pleural fluid for the diagnosis of benign asbestos pleural effusion

Scientific reports, 2021-06, Vol.11 (1), p.12965-12965, Article 12965

2021

Volltextzugriff (PDF)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma

Journal for immunotherapy of cancer, 2020-02, Vol.8 (1), p.e000461

2020

Volltextzugriff (PDF)

Nivolumab for the treatment of unresectable pleural mesothelioma

Expert opinion on biological therapy, 2020-02, Vol.20 (2), p.109-114

2020

Volltextzugriff (PDF)

National survey of malignant mesothelioma and asbestos exposure in Japan

Cancer science, 2012-03, Vol.103 (3), p.483-490

2012

Volltextzugriff (PDF)

Retrospective investigation on diagnostic process for benign asbestos pleural effusion (BAPE) using checklist

Journal of occupational health, 2020-01, Vol.62 (1), p.e12182-n/a

2020

Volltextzugriff (PDF)

Low-dose chest computed tomography screening of subjects exposed to asbestos

European journal of radiology, 2018-04, Vol.101, p.124-128

2018

Volltextzugriff (PDF)

Physician requests by patients with malignant pleural mesothelioma in Japan

BMC cancer, 2019-04, Vol.19 (1), p.383-7, Article 383

2019

Volltextzugriff (PDF)

First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study

Journal of cancer research and clinical oncology, 2022-08, Vol.148 (8), p.1869-1877

2022

Volltextzugriff (PDF)

Subtype of EGFR exon 19 deletion mutations

Translational lung cancer research, 2024-01, Vol.13 (1), p.195-198

Fujimoto, Nobukazu

2024

Volltextzugriff (PDF)

Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study

BMC cancer, 2018-03, Vol.18 (1), p.350-350, Article 350

2018

Volltextzugriff (PDF)

Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma

Cancer science, 2012-03, Vol.103 (3), p.510-514

2012

Volltextzugriff (PDF)

Spare the lung: surgical treatment approach for malignant pleural mesothelioma

Translational lung cancer research, 2023-02, Vol.12 (2), p.197-199

Fujimoto, Nobukazu

2023

Volltextzugriff (PDF)

Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients

BMC cancer, 2019-12, Vol.19 (1), p.1204-9, Article 1204

2019

Volltextzugriff (PDF)

Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404

Japanese journal of clinical oncology, 2021-08, Vol.51 (8), p.1269-1276

2021

Volltextzugriff (PDF)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma

Journal for immunotherapy of cancer, 2021-10, Vol.9 (10), p.e003288

2021

Volltextzugriff (PDF)

Clinical significance of soluble CD26 in malignant pleural mesothelioma

PloS one, 2014-12, Vol.9 (12), p.e115647-e115647

2014

Volltextzugriff (PDF)

Epigenetic Profiles Distinguish Malignant Pleural Mesothelioma from Lung Adenocarcinoma

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (23), p.9073-9082

2009

Volltextzugriff (PDF)

Thrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report

JTO clinical and research reports, 2022-07, Vol.3 (7), p.100351, Article 100351

2022

Volltextzugriff (PDF)

Clinical features of secondary spontaneous pneumothorax complicated with silicosis

Respiratory investigation, 2018-03, Vol.56 (2), p.144-149

2018

Volltextzugriff (PDF)

The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study

Cancers, 2022-12, Vol.14 (24), p.6184

2022

Volltextzugriff (PDF)

Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9056-9056

2019

Volltextzugriff (PDF)

Identification of cancer stem cell markers in human malignant mesothelioma cells

Biochemical and biophysical research communications, 2011-01, Vol.404 (2), p.735-742

2011

Volltextzugriff (PDF)

1 – 25 von 248

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(196)
Mit Volltextzugriff
(234)

Publikationsform

Sprache

Englisch
(219)
Japanisch
(88)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

An appropriate choice for immunotherapy in malignant pleural mesothelioma

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)

Significance of secretory leukocyte peptidase inhibitor in pleural fluid for the diagnosis of benign asbestos pleural effusion

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma

Nivolumab for the treatment of unresectable pleural mesothelioma

National survey of malignant mesothelioma and asbestos exposure in Japan

Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201

Retrospective investigation on diagnostic process for benign asbestos pleural effusion (BAPE) using checklist

Low-dose chest computed tomography screening of subjects exposed to asbestos

Physician requests by patients with malignant pleural mesothelioma in Japan

First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study

Subtype of EGFR exon 19 deletion mutations

Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study

Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma

Spare the lung: surgical treatment approach for malignant pleural mesothelioma

Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients

Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma

Clinical significance of soluble CD26 in malignant pleural mesothelioma

Epigenetic Profiles Distinguish Malignant Pleural Mesothelioma from Lung Adenocarcinoma

Thrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report

Clinical features of secondary spontaneous pneumothorax complicated with silicosis

The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study

Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis

Identification of cancer stem cell markers in human malignant mesothelioma cells

Suchergebnisse filtern